Skip to main content

Advertisement

Table 1 Demographics and clinical characteristics

From: Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease

Characteristics Control group (n = 43) AD group (n = 43) p Value
Sex, M/F, % 47/53 36/64  
Age at examination, yearsa 61 (43–80) 78 (60–94) <0.001
MMSE scorea 29 (24–30) 18 (4–23) < 0.001
APOE ε4 status (−/−, +/−, +/+) 33, 8, 2 12, 24, 7  
CSF Aβ42, pg/mLa 539 (200–990) 335 (140–530) < 0.001
CSF t-tau, pg/mLa 323 (89–690) 700 (360–1990) < 0.001
CSF p-tau, pg/mLa 41 (20–87) 88 (44–226) < 0.001
  1. Abbreviations: AD Alzheimer’s disease, APOE Apolipoprotein E, 42 Amyloid-β 1–42, CSF Cerebrospinal fluid, MMSE Mini Mental State Examination, p-tau Phosphorylated tau, t-tau Total tau
  2. Age at examination, MMSE scores, Aβ42, t-tau and p-tau are presented as median with range
  3. p Values reported are derived from non-parametric comparisons of each pair using Wilcoxon’s method. APOE ε4 genotype status is presented as null (−/−), heterozygous (+/−) and homozygous (+/+)
  4. aMedian (minimum–maximum)